News Janssen's depression drug shows promise in phase 2 Ketamine may be best known as an anaesthetic illegally used as a party drug, but Janssen has shown that it could also be reformulated and used as a treatment for depression.
News Otsuka recruits Medibio to pinpoint mental health biomarkers Medibio's technology will be used to gather mental health biomarkers related to Otsuka's Abilify.
R&D SpringWorks spins out of Pfizer on rare disease mission A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases.
Views & Analysis Progress in mental health digital innovation What new digital technologies are being introduced to help reduce mental illness?
News Verily's Study Watch to feature in major PTSD trial Trial will enrol 5,000 people to determine causes of PTSD.
Views & Analysis Looking back, looking forward – Janssen’s 60 years on the ps... Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.